Oncolink Features

Find My Cancer Drug

Tipos de Cancer / Cánceres Gastrointestinal / Cáncer del Ano / Recursos de NCI

Link to OncoLink

NCI CANCERLIT^® Search: Anal Cancer - July 2002

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 1 de julio del 2002

Adenocarcinoma below ileoanal anastomosis for ulcerative colitis: report of a case and review of the literature.
Contribution of volumetric three-dimensional ultrasound to the prenatal diagnosis of a soft anal tumor.
Adenocarcinoma in the anal canal after ileal pouch-anal anastomosis for ulcerative colitis using a double stapling technique: report of a case.
Management of squamous cell carcinoma of the anus.
Warty carcinoma of the anus: a variant of squamous cell carcinoma associated with anal intraepithelial neoplasia and human papillomavirus
Carcinoma of the anus: strategies in management.
Ten-year results of chemoradiation for anal cancer: focus on late morbidity.
Metastatic renal cell carcinoma presenting as a hemorrhoid.
[Anal carcinoma]
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study.

Table of Contents

1
UI - 12068206
AU - Laureti S; Ugolini F; D'Errico A; Rago S; Poggioli G
TI - Adenocarcinoma below ileoanal anastomosis for ulcerative colitis: report of a case and review of the literature.
SO - Dis Colon Rectum 2002 Mar;45(3):418-21
AD - Unita di Chirurgia, Policlinico S. Orsola, Universita di Bologna, Italy.
BACKGROUND: Restorative proctocolectomy with hand-sewn ileoanal anastomosis and mucosectomy is warranted in patients with dysplasia and/or cancer on ulcerative colitis to prevent subsequent neoplastic changes in the retained mucosa. However, complete excision of the colonic mucosa cannot be obtained reliably. We report a case of anal canal adenocarcinoma after handsewn anastomosis with mucosectomy. METHODS: A 47-year-old patient, previously submitted to ileorectal anastomosis for colonic cancer on ulcerative colitis, underwent completion proctectomy and handsewn ileoanal anastomosis with mucosectomy for recurrent anastomotic cancer. Two years later, we submitted the patient to pouch removal with permanent ileostomy for a mucinous adenocarcinoma of the anal canal (T2N2Mx) found at follow-up pouch endoscopy. CONCLUSIONS: Only four cases of adenocarcinoma after handsewn anastomosis have been reported in the literature. This new case we report confirms that the risk of malignancy after ileoanal anastomosis with mucosectomy, although small, is real, despite the surgeon taking care with this particular step of the procedure. Careful surveillance is needed in patients with surgical treatment for long-term ulcerative colitis or dysplasia.

2
UI - 11982993
AU - Cortes LM; Salamanca SP; Lopez AR; Rayward J; Medina TP; del Barrio
TI - Fernandez P; Arenas JM Contribution of volumetric three-dimensional ultrasound to the prenatal diagnosis of a soft anal tumor.
SO - Ultrasound Obstet Gynecol 2002 May;19(5):526-7

3
UI - 12004221
AU - Baratsis S; Hadjidimitriou F; Christodoulou M; Lariou K
TI - Adenocarcinoma in the anal canal after ileal pouch-anal anastomosis for ulcerative colitis using a double stapling technique: report of a case.
SO - Dis Colon Rectum 2002 May;45(5):687-91; discussion 691-2
AD - 1st Surgical Department and Transplant Unit, "Evangelismos" General Hospital, Athens, Greece.
A case of adenocarcinoma, developed in the anal canal after ileal pouch-anal anastomosis for ulcerative colitis using a double stapling technique, is reported. In this case a T3N0 cecal cancer was found unexpectedly in the colectomy specimen. Two years later, this patient presented with an outlet obstruction of the pouch because of development of an adenocarcinoma of the anal canal. This was treated with an abdominoperineal excision of the pouch and anorectum.

4
UI - 11972565
AU - Erlich R; Hedlund SC; Kulakowski K; Knopp J
TI - Management of squamous cell carcinoma of the anus.
SO - Cancer Pract 2002 May-Jun;10(3):118-21
AD - Medical Oncology, Johns Hopkins Bayview Medical Center, Balitmore, MD, USA.

5
UI - 11701985
AU - Noel JC; Sornin de Leysat C; Peny MO; van de Stadt J; Fayt I; De
TI - Dobbeleer G Warty carcinoma of the anus: a variant of squamous cell carcinoma associated with anal intraepithelial neoplasia and human papillomavirus infection.
SO - Dermatology 2001;203(3):262-4
AD - Department of Pathology, Erasme University Hospital, Free University of Brussels, Belgium. jenoel@ulb.ac.be
Warty carcinoma (WC) is a rare variant of squamous cell carcinoma primarily described in the vulva in younger women and classically associated with human papillomavirus (HPV) infection. The gross findings are similar to those of verrucous carcinoma with large, exophytic tumors with a papillomatous surface. Microscopically, the tumor is papillated and contains fibrovascular cores covered by hyperkeratotic epithelium showing presence of koilocytes. We report a case of anal squamous cell carcinoma showing similar features, occurring in a young immunosuppressed male patient with a history of multifocal anal intraepithelial neoplasia (AIN). HPV-16 has been demonstrated both in the WC and in adjacent AIN, but the HPV status appears different in the two lesions: integrated in WC and episomal in AIN lesions. We also have demonstrated by immunohistochemistry that both WC and AIN are highly proliferative entities sharing the same MIB-1 pattern, and that WAF1/CIP1 protein expression is common in the two lesions irrespective of p53 protein expression. Copyright 2001 S. Karger AG, Basel

6
UI - 12065790
AU - Esiashvili N; Landry J; Matthews RH
TI - Carcinoma of the anus: strategies in management.
SO - Oncologist 2002;7(3):188-99
AD - Emory University School of Medicine, Department of Radiation Oncology, Atlanta, Georgia, USA.
The management of anal cancer underwent an interesting transformation over the last two decades. Prior to this period, the standard definitive treatment for carcinoma of the anal canal was abdominal-perineal resection, which necessitated a permanent colostomy. The organ preservation concept appeared following the discovery of a high complete response rate from preoperative combined chemoradiation prior to abdominal-perineal resection. The organ preservation method of treatment rapidly gained popularity and ultimately saved a large number of patients from undergoing abdominal-perineal resection and colostomy. Chemoradiation treatment itself subsequently went through an evolutionary process. Several studies have sought to define the optimal chemotherapeutic regimen as well as radiation treatment dose and fractionation. Ongoing studies attempt to define an optimal treatment regimen that yields a higher cure rate while minimizing toxicity. We review the etiology, epidemiology, and treatment regimens for anal cancer.

7
UI - 12118566
AU - John M; Flam M; Palma N
TI - Ten-year results of chemoradiation for anal cancer: focus on late morbidity.
SO - Int J Radiat Oncol Biol Phys 1996 Jan 1;34(1):65-9
AD - Central California Cancer Research Group, Fresno, USA.
PURPOSE: To evaluate (a) long-term survival and (b) the incidence and nature of long-term morbidity/ mortality related to chemoradiation using patients), and II (14 patients) cancers of the anal canal were treated definitively with a chemoradiation regimen combining 41.4 Gy pelvic radiotherapy with two concurrent cycles of 5-fluorouracil and mitomycin C. Cumulative actuarial survival was calculated at 10 years and long-term morbidity was categorized per RTOG/EORTC late toxicity criteria. Specific criteria to grade anal toxicity were devised. RESULTS: Cumulative survival for all 34 patients was 92% at 5 years and 85% at 10 years. The most frequent late toxicity was chronic diarrhea in 17 (50%) patients. Five patients (15%) had Grade 3 or 4 late toxicities. Sexual dysfunction was present in 2 of 26 evaluable patients (7%). CONCLUSIONS: Excellent long-term survival and colostomy-free survival is possible for anal cancer patients treated definitively by chemoradiation. Late effects do not appear to be frequent or intense enough to deter the use of chemoradiation in anal cancer. The biologically expected increase in long-term toxicity when combining radiotherapy and chemotherapy is not substantiated by the results of this study.

8
UI - 12088459
AU - Sawh RN; Borkowski J; Broaddus R
TI - Metastatic renal cell carcinoma presenting as a hemorrhoid.
SO - Arch Pathol Lab Med 2002 Jul;126(7):856-8
AD - Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Metastatic, noncolorectal carcinoma involving the anal canal is exceptionally rare, with only 3 cases being described in the medical literature. We report the case of a 53-year-old man with an anal mass clinically presenting as a large, thrombosed, internal hemorrhoid. The patient had a history of nephrectomy for renal cell carcinoma 9 years previously. The resected anal lesion was histologically identical to the primary tumor in the kidney, showing features of renal cell carcinoma of the clear cell type. To the best of our knowledge, this is only the fourth reported case of metastatic, noncolorectal carcinoma involving the anal canal and is the first report of a renal cell carcinoma metastasis to this site.

9
UI - 11765351
AU - Belnome N; Salibra M; Bartolo V; Turrisi M; Cesario E; Di Mauro S
TI - [Anal carcinoma]
SO - Ann Ital Chir 2001 May-Jun;72(3):329-34; discussion 334-5
AD - Cattedra di Chirurgia Generale, Universita degli Studi di Messina.
The authors, want to demonstrate the operation of abdominal perianal rectum amputation, and it is considered absolute, even 80 years, in the treatment of the anal neoplasia, it is superseded by alternative methods represented by protocols radio-chemo-therapeutic associated or less to the surgery treatment. They make then a retrospective valuation since 1963 till our days on 54 patients. In the 6 patients (stadium I-II) treated after 1982 with protocols of freemall, it is was obtained disappearance of the neoplasia about 50% the cases. On overcoming of the results there was in a second group of 8 patients (1987) treated always with protocol of Greenall, in 5 of these (62.5%) could observe absence of remaining of disease. In the third group (1993) on 8 patients treated with therapy fixed radio-chemo, it was registered the absence of the residual of illness in 6 patients(75.5%). Finally, from the analysis of patients observed in the last seven years, 5 of which suffered by Ca squamous in different evolutive stadium (one I stadium, three II stadium and one stadium III-B), the stadium I and II were treated with the protocol radio-chemotherapeutic obtaining total remission of the disease in the 100% of the cases. In the follow-up of 45 patients, 12 of whose were treated with the therapy combined radio-chemo and of these 10 were valuable for survival to 5 years which was about 70% superior to patients treated with only surgery therapy.

10
UI - 12085257
AU - Bjorge T; Engeland A; Luostarinen T; Mork J; Gislefoss RE; Jellum E;
TI - Koskela P; Lehtinen M; Pukkala E; Thoresen SO; Dillner J Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study.
SO - Br J Cancer 2002 Jul 1;87(1):61-4
AD - Department of Pathology, The Norwegian Radium Hospital, 0310 Oslo, Norway. tone.bjorge@oslo.online.no
Human papillomavirus has emerged as the leading infectious cause of cervical and other anogenital cancers. We have studied the relation between human papillomavirus infection and the subsequent risk of anal and perianal skin cancer. A case-cohort study within two large Nordic serum banks to which about 760 000 individuals had donated serum samples was performed. Subjects who developed anal and perianal skin cancer during follow up (median time of 10 years) were identified by registry linkage with the nationwide cancer registries in Finland and Norway. Twenty-eight cases and 1500 controls were analysed for the presence of IgG antibodies to HPV 16, 18, 33 or 73, and odds ratios of developing anal and perianal skin cancer were calculated. There was an increased risk of developing anal and perianal skin cancer among subjects seropositive for HPV 16 (OR=3.0; 95%CI=1.1-8.2) and HPV 18 (OR=4.4; 95%CI=1.1-17). The highest risks were seen for HPV 16 seropositive patients above the age of 45 years at serum sampling and for patients with a lag time of less than 10 years. This study provides prospective epidemiological evidence of an association between infection with HPV 16 and 18 and anal and perianal skin cancer. Copyright 2002 Cancer Research UK

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Ms. Schafer discusses the role of the chaplain and spirituality in cancer care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement